Zobrazeno 1 - 10
of 235
pro vyhledávání: '"Daniel A Vallera"'
Autor:
Antonella Borgatti, Amber L Winter, Kathleen Stuebner, Ruth Scott, Christopher P Ober, Kari L Anderson, Daniel A Feeney, Daniel A Vallera, Joseph S Koopmeiners, Jaime F Modiano, Jerry Froelich
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172651 (2017)
Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly available in veterinary medicine. In this study, 18-fluorodeoxyglucose (18FDG)-PET-CT was use
Externí odkaz:
https://doaj.org/article/f1483c8f3fc04647845ddb2059e0f23d
Autor:
Rose H. Dicovitsky, Jill T. Schappa, Ashley J. Schulte, Haeree P. Lang, Ellen Kuerbitz, Sarah Roberts, Taylor A. DePauw, Mitzi Lewellen, Amber L. Winter, Kathy Stuebner, Michelle Buettner, Kelly Reid, Kelly Bergsrud, Sara Pracht, Andrea Chehadeh, Caitlin Feiock, M. Gerard O’Sullivan, Tim Carlson, Alexandra R. Armstrong, Danielle Meritet, Michael S. Henson, Brenda J. Weigel, Jaime F. Modiano, Antonella Borgatti, Daniel A. Vallera
Publikováno v:
Toxins, Vol 16, Iss 9, p 376 (2024)
EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only emerging, so neither their efficacy nor toxicity is fully established. Recombinant eBAT wa
Externí odkaz:
https://doaj.org/article/6505ce6cd7b5471f92672f457ebc37f6
Publikováno v:
Immuno, Vol 3, Iss 2, Pp 237-249 (2023)
Chemotherapy-refractive multiple myeloma (MM) is serious and life-threatening, and better treatments are urgently needed. BCMA is a prominent marker on the cell surface of MM cells, rendering it an accepted target for antibody therapy. Considering th
Externí odkaz:
https://doaj.org/article/3e58da5685194a748d30a8678bd5e8c9
Autor:
Philippa R. Kennedy, Daniel A. Vallera, Brianna Ettestad, Caroline Hallstrom, Behiye Kodal, Deborah A. Todhunter, Laura Bendzick, Peter Hinderlie, Joshua T. Walker, Brittany Pulkrabek, Ira Pastan, Robert A. Kratzke, Naomi Fujioka, Jeffrey S. Miller, Martin Felices
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
New treatments are required to enhance current therapies for lung cancer. Mesothelin is a surface protein overexpressed in non-small cell lung cancer (NSCLC) that shows promise as an immunotherapeutic target in phase I clinical trials. However, the i
Externí odkaz:
https://doaj.org/article/cf1f398a8d974c5e8e36f681326c38aa
Autor:
Hyun Don Yun, Martin Felices, Daniel A. Vallera, Peter Hinderlie, Sarah Cooley, Michel Arock, Jason Gotlib, Celalettin Ustun, Jeffrey S. Miller
Publikováno v:
Blood Advances, Vol 2, Iss 13, Pp 1580-1584 (2018)
Externí odkaz:
https://doaj.org/article/1c48f57515a74fe4ba37ba09d3eb3313
Autor:
Dhifaf Sarhan, Ludwig Brandt, Martin Felices, Karolin Guldevall, Todd Lenvik, Peter Hinderlie, Julie Curtsinger, Erica Warlick, Stephen R. Spellman, Bruce R. Blazar, Daniel J. Weisdorf, Sarah Cooley, Daniel A. Vallera, Björn Önfelt, Jeffrey S. Miller
Publikováno v:
Blood Advances, Vol 2, Iss 12, Pp 1459-1469 (2018)
Abstract: Myelodysplastic syndrome (MDS) is a clonal heterogeneous stem cell disorder driven by multiple genetic and epigenetic alterations resulting in ineffective hematopoiesis. MDS has a high frequency of immune suppressors, including myeloid-deri
Externí odkaz:
https://doaj.org/article/0305f116a4114bdda91c6b8ab45c6574
Autor:
Daniel A. Vallera, Jaime F. Modiano, Kristy Pilbeam, Felix Oh, Kerstin Lindblad-Toh, Matthew Breen, Michael S. Henson, Jillian Walz, Jerry Froelich, Jong-Hyuk Kim, Colleen L. Forster, Stephen Schmechel, Jonathan C. Henriksen, Anthony E. Rizzardi, Deborah Todhunter, Kathleen Stuebner, Amber L. Winter, Aaron L. Sarver, Joseph S. Koopmeiners, Antonella Borgatti
Detailed Methods for Immunohistochemistry Detailed Description of the Canine Clinical Study eBAT Pharmacokinetics and Neutralizing Antibody Assays Supplementary Table 1. Correlation between patient covariates and death Supplementary Table 2: Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a4aa52c0607ee0942297b84a938356
https://doi.org/10.1158/1535-7163.22505770
https://doi.org/10.1158/1535-7163.22505770
Supplementary data and supplementary figures 1-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84a2d7fe91ba14f86aa3502b600bb506
https://doi.org/10.1158/1535-7163.22523242.v1
https://doi.org/10.1158/1535-7163.22523242.v1
Autor:
Daniel A. Vallera, Jaime F. Modiano, Kristy Pilbeam, Felix Oh, Kerstin Lindblad-Toh, Matthew Breen, Michael S. Henson, Jillian Walz, Jerry Froelich, Jong-Hyuk Kim, Colleen L. Forster, Stephen Schmechel, Jonathan C. Henriksen, Anthony E. Rizzardi, Deborah Todhunter, Kathleen Stuebner, Amber L. Winter, Aaron L. Sarver, Joseph S. Koopmeiners, Antonella Borgatti
Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor and tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a17472aa6c47bead566c16a06a42417
https://doi.org/10.1158/1535-7163.c.6538177.v1
https://doi.org/10.1158/1535-7163.c.6538177.v1
Autor:
Jeffrey S. Miller, Bruce R. Blazar, Daniel J. Weisdorf, Sarah Cooley, Jakub Tolar, Michael R. Verneris, Angela Panoskaltsis-Mortari, Alexander J. Lenvik, Bin Zhang, Joerg Uwe Schmohl, Xianzheng Zhou, Valarie McCullar, Ron McElmurry, Martin Felices, Daniel A. Vallera
BiKE and TriKE selectively bind antigen expressing targets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c1613539f70e5c17ea7a3560a26cd4
https://doi.org/10.1158/1078-0432.22457925
https://doi.org/10.1158/1078-0432.22457925